SCHEMBL7679836

SCHEMBL7679836

CC(F)(OC(C)(F)C(F)(F)F)C(F)(F)F

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17779739 0.85
SCHEMBL17324163 0.85
SCHEMBL15468507 0.82
SCHEMBL890401 0.77
SCHEMBL16473068 0.77
SCHEMBL12603950 0.77
SCHEMBL14561703 0.75
SCHEMBL1029486 0.75 ALDH1A1 (0.33) ALDH1A1
SCHEMBL14231624 0.75
SCHEMBL10040943 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10899692-B2 Purification method and production method of difluoromethyl-1, 2, 2, 2-tetrafluoroethyl ether CENTRAL GLASS COMPANY, LIMITED (JP) 2021-01-26 US claimed
US-20200339494-A1 Purification Method and Production Method of Difluoromethyl-1, 2, 2, 2-Tetrafluoroethyl Ether CENTRAL GLASS COMPANY, LIMITED (JP) 2020-10-29 US claimed
CN-111556859-A Method for purifying difluoromethyl-1, 2,2, 2-tetrafluoroethyl ether and process for producing the same 中央硝子株式会社 2020-08-18 CN claimed
CN-101535231-B Process for the preparation of chloromethyl 2,2,2-trifluoro-1-(trifluoromethyl) ethyl ether CRISTALIA PROD QUIMICOS FARM 2012-12-19 CN claimed
CN-101314560-B Process for synthesizing Sevoflurane LUNAN PHARM GROUP CORP 2011-06-15 CN claimed
CN-101535231-A Process for the preparation of chloromethyl 2,2,2-trifluoro-1-(trifluoromethyl) ethyl ether CRISTALIA PROD QUIMICOS FARM 2009-09-16 CN claimed
CN-101314560-A Process for synthesizing Sevoflurane LUNAN PHARM GROUP CORP (CN) 2008-12-03 CN claimed
JP-3252391-B2 2002-02-04 JP claimed
EP-0642486-B1 PRODUCTION OF HYDROFLUOROCARBONS FROM alpha-FLUOROETHERS AND SOME alpha-FLUOROETHERS ICI PLC (GB) 1999-06-02 EP claimed
EP-0642486-A1 PRODUCTION OF HYDROFLUOROCARBONS FROM $g(a)-FLUOROETHERS AND $g(a)-FLUOROETHERS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1995-03-15 EP claimed
WO-1993012057-A1 PRODUCTION OF HYDROFLUOROCARBONS FROM α-FLUOROETHERS AND α-FLUOROETHERS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-06-24 WO claimed
WO-2023157441-A1 ETCHING METHOD 株式会社レゾナック 2023-08-24 WO disclosed
CN-111556859-B Method for purifying difluoromethyl-1, 2-tetrafluoroethyl ether and process for producing the same 中央硝子株式会社 2022-10-25 CN disclosed
US-10899692-B2 Purification method and production method of difluoromethyl-1, 2, 2, 2-tetrafluoroethyl ether CENTRAL GLASS COMPANY, LIMITED (JP) 2021-01-26 US disclosed
US-20200339494-A1 Purification Method and Production Method of Difluoromethyl-1, 2, 2, 2-Tetrafluoroethyl Ether CENTRAL GLASS COMPANY, LIMITED (JP) 2020-10-29 US disclosed
US-5696308-A HEATING AN ALPHA-FLUOROETHER IN THE VAPOR PHASE WITH HYDROGEN FLUORIDE IN THE PRESENCE OF A CATALYST IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1997-12-09 US disclosed
US-5637776-A ACYCLIC FLUORINATED ETHER IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1997-06-10 US disclosed
US-5504263-A HEATING ALPHA-FLUOROETHER IN VAPOR PHASE AT ELEVATED TEMPERATURE INPRESENCE OF HYDROGEN FLUORIDE AND CATALYST IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1996-04-02 US disclosed
EP-0642486-A1 PRODUCTION OF HYDROFLUOROCARBONS FROM $g(a)-FLUOROETHERS AND $g(a)-FLUOROETHERS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1995-03-15 EP disclosed
WO-1993012057-A1 PRODUCTION OF HYDROFLUOROCARBONS FROM α-FLUOROETHERS AND α-FLUOROETHERS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200339494-A1 Purification Method and Production Method of Difluoromethyl-1, 2, 2, 2-Tetrafluoroethyl Ether TDO2, PBRM1, AFF1 ALDH1A1 1290/4885
US-10899692-B2 Purification method and production method of difluoromethyl-1, 2, 2, 2-tetrafluoroethyl ether TDO2, PBRM1, AFF1 ALDH1A1 1290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.